PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 40: Articles 19501-20000 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. Oral contraception and carbohydrate metabolism--the physiopathological explanation. [Contraception orale et metabolisme glucidique II--les explications physiopathologiques.]
  2. Oral contraception and coagulation.
  3. Oral contraception and serious psychiatric illness: absence of an association.
  4. Oral contraception--starting, stopping or changing.
  5. Oral contraceptive agents and coronary disease (letter) [Orale antikoncepsjonsmidler og koronarsykdom.]
  6. Oral contraceptive drug interactions.
  7. The oral contraceptive pill and benign intracranial hypertension [letter]
  8. Oral contraceptive practice.
  9. Oral contraceptive use and blood pressure in a German metropolitan population.
  10. Oral contraceptive use and breast cancer in young women in Sweden [letter]
  11. Oral contraceptives and blood platelets. [Contraceptifs oraux et plaquettes sanguines.]
  12. Oral contraceptives and breast cancer in young women.
  13. Oral contraceptives and breast cancer: epidemiological evidence.
  14. Oral contraceptives and breast cancer: laboratory evidence.
  15. Oral contraceptives and breast cancer: the current controversy.
  16. Oral contraceptives and breast, endometrial, and ovarian cancers. The Cancer and Steroid Hormone Study Group, Atlanta Georgia.
  17. Oral contraceptives and breastfeeding: haematological effects on the infant.
  18. Oral contraceptives and cancer of the reproductive organs.
  19. Oral contraceptives and cervical cancer.
  20. Oral contraceptives and coronary heart disease.
  21. Oral contraceptives and nonfatal vascular disease.
  22. Oral contraceptives and nutrition interaction.
  23. Oral contraceptives and pelvic inflammatory disease.
  24. Oral contraceptives and prognosis of breast cancer in women aged 35 to 50.
  25. Oral contraceptives and the cobalamin (vitamin B12) metabolism.
  26. Oral contraceptives and tumors. [Ovulationshemmer und Tumoren.]
  27. Oral contraceptives come of age.
  28. Oral contraceptives may increase risk of Chlamydial infection.
  29. Oral contraceptives, 1985 : a synopsis.
  30. Oral contraceptives, Chlamydia trachomatis and PID.
  31. Oral contraceptives: the state of the art.
  32. Oral glucose tolerance and the potency of contraceptive progestins.
  33. The oral pill in the Indonesian Population/Family Planning Program.
  34. Ordinance No. 14 of 28 December 1984 of the Minister of Health on the use and marketing of intrauterine contraceptives.
  35. Our experience with Gyne-T Cu 380-A, an intrauterine contraceptive device (1983-1984) [Notre experience du Gyne-T Cu 380-A, dispositif intra-uterin (1981-1984)]
  36. Outreach: a luxury or a necessity? A quantitative look at mobile family planning services in Tunisia.
  37. An overview of operations research methods for improving management decisionmaking in health and family planning.
  38. Packages for contraceptive products designed for social marketing projects. [Conditionnements de produits contraceptifs elabores pour des projets de commercialisation sociale. Envases para productos anticonceptivos disenados para proyectos de mercadeo social.]
  39. Paradoxical improvement of glucose intolerance in 8 women using combined contraceptives containing norgestrel and ethinyl-estradiol. [Amelioration paradoxale de l'intolerance au glucose chez 8 femmes sous contraception oestroprogestative contenant du norgestrel et de l'ethinyl-oestradiol.]
  40. Participant evaluation of the Population Communication and Research Workshop sponsored by Social Development Center, International Planned Parenthood Federation, Western Hemisphere, United States Agency for International Development, Latin American and Caribbean Bureau, Held in Chicago, Illinois, August 26 to September 13, 1985.
  41. Partnership, sexuality and contraception in the mentally retarded. [Partnerschaft, Sexualitat und Kontrazeption bei geistig behinderten Menschen.]
  42. Patient understanding of oral contraceptive side effects.
  43. Patients with hematologic disorders need careful birth control counseling.
  44. Patterns of contraceptive method of use by California family planning clinic clients, 1976-84.
  45. Peliosis hepatis and oral contraceptives: a case report. [Peliose hepatique et oestroprogestatifs: a propos d'un cas revele par une ascite.]
  46. Pelvic actinomycosis in users of intrauterine contraception. [Panvova aktinomykoza u uzivateliek intrauterinnej antikoncepcie.]
  47. Pelvic inflammatory disease, intrauterine contraception, and the conduct of epidemiologic studies.
  48. Peptide contraception in women. Inhibition of ovulation by chronic intranasal LRH agonist therapy.
  49. Perspectives of family planning in developing countries: some lessons learned from the WFS.
  50. Pharmacodynamic evaluation of the benzodiazepine--oral contraceptive interaction.
  51. Phase II clinical study of implanted norethindrone pellets for longterm contraception in women.
  52. Photosensitized decomposition of contraceptive steroids: a possible explanation for the observed (photo)allergy of the oral contraceptive pill.
  53. The pill: hazards and benefits: its potential place on the world scene of contraception. [La pilule: les hazards et ses benefices sa place potentielle dans la scene mondiale de la contraception.]
  54. Pilot study on the role of community communication: networks on the acceptance and continuation of family planning practice.
  55. The "pioneers": users of family planning in Senegal--Dakar, 1983. [Les "pionnieres": utilisatrices de la planification familiale au Senegal--Dakar, 1983.]
  56. Planned Parenthood and Women's Development. Experiences from Africa: Ghana, Kenya, Lesotho and Mauritius.
  57. Planned Parenthood education programs: a national overview.
  58. Planned Parenthood Federation of America: its role as provider of information services.
  59. Planning a family - contraception.
  60. Planning and conducting campaigns and programs for contraceptive education. A training manual for communicators and educators.
  61. Plant contraceptives: translating folklore into scientific application.
  62. Policy statement on male involvement in family planning.
  63. Population and family planning in India: a select bibliography.
  64. Population and family planning programs in Latin America, 1974-1984.
  65. Population and family planning programs: a compendium of data through 1983, 12th ed.
  66. Population and family planning research, Bangladesh: an annotated bibliography, 3rd ed.
  67. Population and family planning.
  68. Population growth, health and family planning.
  69. Population policies, birth control, and health among women inM. [Bevolkingspolitiek, geboortenregeling en gezondheid van vrouwen in Mexico.]
  70. Population/family planning information services 1974-1984.
  71. Population/family planning information services 1974-1984.
  72. Population/family planning information services--a decade later.
  73. Population: Norplant subdermal contraceptive implant--update.
  74. Possible cohort effects in studies on oral contraceptive use and breast cancer [letter]
  75. Possible potentiation of suicide risk in patients with EEG dysrhythmias taking oral contraceptives: a speculative empirical note.
  76. Post natal consultation after 40 days at the Wassila Bourguiba de SFAX center, "New approach to integrated contraception". [La consultation post natale du 40eme jour au centre Wassila Bourguiba de SFAX "Approche nouvelle d'une contaception integree".]
  77. Post-coital contraception.
  78. Post-coital contraception. [La contraception post-coitale.]
  79. Post-coital contraception. [La contraception post-coitale.]
  80. Postcoital contraception using a combination of d-norgestrel and ethinylestradiol. [Interception post-coitale avec une association de d-norgestrel et d'enthinyloestradiol.]
  81. Postcoital contraception.
  82. Postcoital contraception.
  83. Postcoital contraception.
  84. Postcoital contraception. [Postkoitalma kontracepcija.]
  85. Postcoital contraception. [Postkoitalna kontracepcija.]
  86. Postcoital contraception: a report from the London Brook Advisory Centres, United Kingdom.
  87. Postpartum contraception (letter) [Kontrazeption post partum.]
  88. Potential long-acting contraceptive agents: esters and ethers of testosterone with alpha- and/or beta-chain branching.
  89. Potential use of postcoital contraception to prevent unwanted pregnancy.
  90. Preclinical and clinical aspects of safety in contraception.
  91. Predicting contraceptive behavior among college students: the role of communication, knowledge, sexual anxiety, and self-esteem.
  92. Pregnancy-related health services. Hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, Ninety-Ninth Congress, First Session, on: prevention of low birth weight, February 25, 1985; adolescent pregnancy and reauthorization of Adolescent Family Life Act--H.R. 927, March 21, 1985, [and] Family Planning Act reauthorization, March 27, 1985.
  93. Premarital contraceptive use: a discriminant analysis approach.
  94. Prescribing information: Copper T model TCu 200B brand of intrauterine copper contraceptive.
  95. Prescribing information: Copper T model TCu 380A brand of intrauterine copper contraceptive.
  96. Prescription contraceptives: countering the risks.
  97. Present and future aspects of immunological methods in contraception.
  98. The present state of male contraception. [Soucasny stav muzske antikoncepce.]
  99. The present state of research on the relationship of oral contraceptives to breast cancer. [Etat actuel de la recherche sur les relations entre contraceptifs oraux et cancer du sein.]
  100. The press and the beginning of the birth control movement in the United States.
  101. Prevalence and trends in oral contraceptive use in premenopausal females ages 12-54 years, United States, 1971-80.
  102. A prevalence model for evaluating the fertility effect of family planning programmes: age-specific and method-specific results.
  103. Prevalence, perception, perspectives, on methods of birth control in Tunisia. [Prevalnce, perception, perspectives, des methodes de regulation des naissances en Tunisie.]
  104. Price elasticity of demand for contraceptives: Jamaica and Thailand.
  105. Pricing and cost recovery experience in family planning programs.
  106. Principles of oral contraception.
  107. Private sector family planning.
  108. Problems in evaluating the family planning impact of a comprehensive health delivery system in India.
  109. Problems of contraception in the school environment. [Problemes poses par la contraception en milieu scolaire.]
  110. Problems of implementation of family planning projects, as components of population programmes.
  111. Problems related to the development and implementation of the applied study in Mexico: the case of sexual and contraceptive attitudes and practices in adolescents and young people. [Problemas relacionados con el desarrollo e implementacion de la investigacion aplicada en Mexico: el caso de las actitudes y practicas sexuales y anticonceptivas en adolescentes y jovenes.]
  112. Proceedings of the Seventeenth Annual Conference, Association for Population/Family Planning Libraries and Information Centers--International, Northstar Hotel, Minneapolis, Minnesota, April 30-May 3, 1984. World population year: a decade later.
  113. Production and broadcasting of television/video programs of family planning/maternal and child health.
  114. Profiles of family planning acceptors in the national programme.
  115. Pros and cons of triphasic oral contraception. [Avantages et inconvenients de la contraception orale triphasique.]
  116. A prospective trial of the mucothermic method of natural family planning.
  117. Prostaglandins in contraception.
  118. Protein C levels in late pregnancy, postpartum and in women on oral contraceptives.
  119. Prototype home-based mother's record: a guideline for its use, and adaptation in maternal and child health/family planning programmes and a reference manual for field testing and evaluation.
  120. Providing sexually transmissible disease services and general screening physicals to men in a community-based family planning center.
  121. Psychological factors related to post-abortion 'subtle' contraceptive unreliability.
  122. Psychological problems linked to the puerperium and contraceptive usage. [Troubles psychiques lies a la puerperalite et mesures contraceptives.]
  123. Psychology of contraception. [Quelques approches psychologiques de la contraception.]
  124. Psychosocial research and family planning services in Mexico. [La investigacion psicosocial y de servicios sobre planificacion familiar en Mexico.]
  125. Public attitudes about sex education, family planning, and abortion in the United States.
  126. Public concerns about family planning programs and teens. The problem or the solution.
  127. Public perceptions of four contraceptive methods in Egypt.
  128. Publicity for family planning must be based on serving the masses.
  129. Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill.
  130. The question of birth control. [A questao do controle da natalidade.]
  131. Questionnaire about contraceptive methods. [Inquerito sobre o uso de metodos anticoncepcionais.]
  132. Radio and family planning in Israel: letters to broadcasters.
  133. RAMOS study confirms contraception saves lives.
  134. A rare form of benign tumor of the liver possibly related to the use of oral contraceptives: focal pediculated nodular hyperplasia. [Une forme rare de tumeur benigne du foie en relation possible avec l'utilisation de contraceptifs oraux: l'hyperplasie nodulaire focale pediculee.]
  135. The real and false risks of local contraception: spermicides and the diaphragm. [Risques vrais et faux de la contraception locale: spermicides, diaphragme.]
  136. Reasons for family planning method switching in Northeastern Thailand: an experimental study of a motivational strategy.
  137. Reasons for non-practice and future utilization of contraception in Morocco and in Tunisia. [Raisons de la non pratique et utilisation future de la contraception au Maroc et en Tunisie.]
  138. Recent developments in female contraception: LHRH.
  139. Recent trends in contraceptive use in Canada.
  140. Recommendations of the Second Expert Group Meeting on Methods of Measuring the Impact of Family Planning Programmes on Fertility.
  141. Reduced risk of pelvic inflammatory disease with injectable contraceptives.
  142. Reflections on a new generation of oral contraceptives. [Reflexions sur une nouvelle generation de contraceptifs oraux.]
  143. Refresher course on family planning.
  144. The relation of fertility desires to contraceptive use: interpretation of changes over time and place.
  145. Relationship between congenital anomalies and contraception.
  146. The relationship between egocentrism and contraceptive behavior for adolescents.
  147. Relationship of exercise, oral contraceptive use, and body fat to concentrations of plasma lipids and lipoprotein cholesterol in young women.
  148. The relationship of self-concept and autonomy to oral contraceptive compliance among adolescent females.
  149. Release of copper from intrauterine contraceptive device Copper T-200. [Uwalnianie miedzi z antykoncepcyjnych wkladek wewnatrzmacicznych Copper T-200.]
  150. Religion and family planning.
  151. Religious correlates of male sexual behavior and contraceptive use.
  152. Renin-angiotensin system: oral contraception and exercise in healthy female subjects.
  153. Report of the sixth annual workshop in family planning, nutrition, and primary health care for Africa: program design, management and evaluation.
  154. Report of the Third Expert Group Meeting on Methods of Measuring the Impact of Family Planning Programmes on Fertility.
  155. Report on international financial resources for maternal/child health and family planning.
  156. Reproductive decisions and contraceptive use in a Chinese new village in Malaysia.
  157. Reproductive health knowledge, sexual behavior and contraceptive practice among the adolescent population in Monrovia, Liberia.
  158. Research breakthroughs unlikely without major new NIH support. Contraception in the eighties.
  159. Research into community participation in family planning projects summary of progress 1981-1985.
  160. Research report on a comparative analysis of the government and private family planning programs in the southern region of Thailand.
  161. Residual vascular risk of discontinued oral contraception: role of antibodies to synthetic sex hormones.
  162. Resistance and compliance to contraception in adolescents. [Resistance et compliance a la contraception a l'adolescence.]
  163. Response to] Further pregnancy after CVA while on oral contraceptives [letter]
  164. Retinal manifestations of thrombotic thrombocytopenic purpura (TTP) following use of contraceptive treatment.
  165. Review of population/family planning related needs of adolescents in Thailand.
  166. A review of the Population and Family Planning Services Project, USAID/Jamaica.
  167. Revolution in reproduction: family planning in an Appalachian community.
  168. The rise of modern contraception.
  169. Risk analysis of hormonal contraception. [Risikoanalyse der hormonalen Kontrazeption.]
  170. The risk of an unwanted birth: the changing context of contraceptive sterilization in the U.S.
  171. Risk-takers' attitudes towards contraception and pregnancy.
  172. Role of demographic and socio-economic factors in contraceptive methods. [Methodes contraceptives roles des facteurs socio-economiques et demographiques.]
  173. Role of intrauterine devices in the family planning program of India.
  174. The role of modern family planning in southwestern Nigeria: the setting for a village-based family planning program.
  175. Role of reproduction and contraception in the epidemio-genesis and control of tuberculosis.
  176. The role of the IUD in the Indonesian National Family Planning Program.
  177. The role of traditional healers in the provision of health care and family planning services: Ayurveda and Sidda.
  178. The role of traditional healers in the provision of health care and family planning services: Malay traditional and indigenous medicine.
  179. The role of traditional healers in the provision of health care and family planning services: Sinseh.
  180. Role of village practitioners in family planning service delivery system.
  181. Rubella susceptibility among prenatal and family planning clinic populations.
  182. Rural availability of contraceptive services.
  183. Rural electrification, fertility change, and family planning practice in the Southern Philippines: a preliminary analysis.
  184. Rural women's development and family planning.
  185. Rural-urban differential in contraceptive use status in Bangladesh.
  186. Scaling contraceptive use motivation in the Matlab Family Planning Health Services Project: a factor analytic approach.
  187. Scanning electron microscopy as an analytical tool for the study of calcified intrauterine contraceptive devices.
  188. Scanning electron microscopy, x-ray diffraction, and electron microprobe analysis of calcific deposits on intrauterine contraceptive devices.
  189. Schooling, information and non-market productivity: contraceptive use and its effectiveness.
  190. Searching for ideal contraceptives.
  191. Selected papers of the 1984 Annual Conference of the National Council for International Health. Conference theme--international health and family planning: controversy and consensus, June 11-13, 1984, Arlington, Virginia.
  192. Selection of an appropriate method for evaluation of the demographic impact of a family planning programme.
  193. Self-instruction manual in contraceptive methods especially for APROFAM personnel. [Manual de autoinstruccion de metodologia anticonceptiva especial para personal de APROFAM.]
  194. Selling family planning in Ghana. [La vente du planning familial au Ghana.]
  195. Serum prolactin levels in woman using oral contraceptives (Gravistat) [Stezenia prolaktyny w surowicy krwi u kobiet stosujacych doustne srodki antykoncepcyjne (Gravistat)]
  196. Services for adolescents: some family planning association initiatives.
  197. Sex and contraceptive information for adolescents. [L'information sexuelle et contraceptive chez les adolescents.]
  198. Sex information and contraception. [Information sexuelle et contraception.]
  199. Sex ratio associated with natural family planning [letter]
  200. Sex ratio associated with natural family planning. Reply of the author [letter]
  201. The shady side of contraception. [Les dessous de la contraception.]
  202. Short-term population/family planning/maternal-child health training programs.
  203. Sister-chromatid exchange studies in women with long-term use of the oral contraceptive pills megestrol acetate compositas.
  204. Sixteen year old patient with deep leg and pelvic venous thrombosis after taking contraceptives. [Tiefe Bein-Beckenvenen-Thrombose bei 16jahriger Patientin nach Einnahme eines Antikonzeptivums.]
  205. Social and demographic factors influencing the acceptability of injectable method for contraception in comparison with copper T I.U.D.
  206. Social and environmental factors influencing contraceptive use among black adolescents.
  207. The social effects of contraception.
  208. Social factors affecting contraceptive use.
  209. Social marketing of contraceptives. A brief to advertising agencies.
  210. Social skills and responses in simulated contraceptive problem situations.
  211. Social structure and family planning: a case study of two tribal villages.
  212. Sociedade Civil Bem-Estar Familiar no Brasil (BEMFAM): review of an integrated family planning and antihelminthic therapy project in Piaui State, Brazil.
  213. Socio-cultural factors influencing family planning in Egypt, and policy redirections.
  214. Socio-medical factors affecting the utilization of different contraceptive methods at Al-Azhar rural family health clinic.
  215. Socioeconomic determinants of contraceptive innovation: a focus on heterogeneous socialization experiences.
  216. Some observations on the concepts of contraceptive supply and demand.
  217. A specific evaluation of family life education on contraceptive use and pregnancy among teens.
  218. Spermicidal contraceptives and poor reproductive outcomes [letter]
  219. Spermicidal contraceptives and poor reproductive outcomes: the epidemiologic evidence against an association.
  220. The St. Kitts-Nevis male family planning survey country report 1982.
  221. State laws and the provision of family planning and abortion services in 1985.
  222. Statement on Norplant subdermal contraceptive implant system.
  223. Sterilization approval and follow through: results from a family planning program in Brazil.
  224. Sterilization counseling in the United States: applications to international family planning services.
  225. Steroid-induced side-effects of oral contraceptives.
  226. Steroidal contraception--experimental background.
  227. Strengthening family planning management.
  228. Stroke and combined oral contraceptives. [Accidents vasculaires cerebraux et oestroprogestatifs de synthese.]
  229. A strong national framework for family planning services. Title X of the Public Health Service Act.
  230. Structure of a radiate pseudocolony associated with an intrauterine contraceptive device.
  231. Studies to enhance the evaluation of family planning programmes.
  232. A study of adolescent contraceptive practices: examining attitudes of locus of control and feminism.
  233. A study of factors related to contraceptive dropout: colored women in the metropolitan area of Capetown. [Nondersoek na faktore wat met kontraseptiewe staking verband hou: kleurlingvroue in die metropolitaanse gebied van kaapsted.]
  234. A study of family planning incentive programs in Thailand: a research report.
  235. A study of the effectiveness of the village health communicator and the village health volunteer upon the family planning of Buddhist and Muslim couples in southern Thailand.
  236. A study of the influence of ovulation stimulants and oral contraception on twin births in England.
  237. A study of the perceptions of middle school girls regarding the factors which influence their knowledge, attitudes and behaviors concerning the use or the non-use of contraceptives.
  238. A study of the performance of the Oyo State community-based health/family planning workers.
  239. Study on acceptance of family planning.
  240. A study on the association between the use of oral contraception and cancer of the breast or cervix: preliminary findings of a French study. [Etude de la relation entre contraception orale et cancer du sein ou du col uterin: resultats preliminaires k'une enquete francaise.]
  241. Subdermal contraceptive implants [letter]

     

  242. The Sudan Community-Based Health and Family Planning Project: description of a training course.
  243. Sulpiride and the potentiation of progestogen only contraception [letter]
  244. Sulpiride and the potentiation of progestogen only contraception [letter]
  245. Sulpiride and the potentiation of progestogen only contraception--the author's reply [letter]
  246. Summary views on the economics of family planning in Bangladesh.
  247. Supervising community health workers in community-based delivery of primary health/family planning services: experiences in Mexico, 1977-1982.
  248. Supply and demand for contraception: reflection on the Algerian experience in family planning centers. [Offre et demande de contraception: reflexion sur l'experience Algerienne des centeres d'espacement des naissances.]
  249. Surface changes in intrauterine contraceptive devices after variable use.
  250. Survey and analysis of family planning work at Xindian Brigade.
  251. Survey measurement of contraceptive service availability: the 1982 rural Mexican experience with issues of level, metric and matching.
  252. A survey of the family planning work done in Dongguan County.
  253. Synphase--another triphasic oral contraceptive.
  254. Technical assistance for redesign of contraceptive supplies project in Ghana.
  255. Technical measures for family planning in China.
  256. Teenage attitudes on and practice of contraception and abortion in Hungary and worldwide. [A serdulokoruak fogamzasgatlasi magatartasanak es terhessegmegszakitasanak nemzetkozi es magyarorszagi jellemzoi.]
  257. Teenagers and contraception: evaluation of the first year at the contraceptive guidance clinic in Sor-Varanger. [Ungdom og prevensjon. Evaluering av ett ars drift ved Prevensjonskontoret i Sor-Varanger.]
  258. Teenagers talk about sex, pregnancy, and contraception.
  259. Ten year report. Concerned Women for Family Planning. A decade of pioneering venture.
  260. Teratogenic and mutagenic risks of radiotherapy: when and how to prescribe contraception. [Risques teratogenes et mutagenes d'une radiochimiotherapie: quand et comment prescrire une contraception.]
  261. Thailand Third Contraceptive Prevalence Survey: summary report.
  262. Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives.
  263. Three triphasic oral contraceptives now available in U.S.
  264. Thrombosis due to permanent pacemaker and oral contraceptives.
  265. To educate and organize youth for the family planning promotion [Annual report to IPPF]
  266. Toxic shock syndrome associated with the use of the vaginal contraceptive sponge [letter]
  267. Traditional methods of birth control.
  268. Training CBD workers for family planning and health interventions.
  269. Training for voluntary surgical contraception. Preliminary report of an Expert Committee, Rio de Janeiro, September 16-28, 1984.
  270. Transient ischemic attack (T.I.A.) in a patient with non-thrombogenic hereditary protein C deficiency under oral contraceptives [letter]
  271. Travel behavior among current contraceptive users: the influence of contraceptive accessibilty on actual use.
  272. Trends in family planning in Croatia. [Pokazatelji planiranja obitelji u SR Hrvatskoj.]
  273. Trial of gossypol as a male contraceptive.
  274. Trip report on technical assistance to three family planning training activities in Egypt.
  275. Trip report, Nigeria, October 13 - November 3, 1985. Purpose: to implement 2 five-day family planning and oral rehydration therapy update workshops in Anambra State for a total of 60 nurse/midwives.
  276. Trip report. Nepal Family Planning/Maternal Child Health Project: field evaluation of pill and condom booklets, AS-NEP-01.
  277. Trip report: family planning communication technical assistance mission to Costa Rica and Honduras.
  278. Twenty points for family planning.
  279. Two decades of United States support for family planning. At home and abroad.
  280. Ultrasonic visualization of Norplant subdermal contraceptive devices.
  281. Ultrasonic, biochemical and cervical mucous studies in contraceptives users.
  282. Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435.
  283. Underage contraception.
  284. Unintended effects of oral contraceptives--I. Estrogen-induced effects. [Unbeabsichtigte Wirkungen der oralen Kontrazeptiva I. Ostrogenbedingte Effekte.]
  285. Unwanted pregnancy after careful contraception. [Ongewenste zwangerschap na zorgvuldige anticonceptie.]
  286. Update on oral contraceptives.
  287. Update on the new triphasic oral contraceptives [letter]
  288. Urological complications secondary to a contraceptive diaphragm.
  289. USAID analyses and strategy for assistance in family planning and fertility reduction in Kenya.
  290. The use and prevalence of contraception in some countries of the American region.
  291. The use of computer simulation programming in improving the design of family planning clinics.
  292. The use of contraception among abortion applicants.
  293. The use of contraception in the Asian and Pacific region.
  294. The use of contraception. Results of an inquiry into the population at risk. [Le vecu de la contraception. Resultats d'une enquete aupres d'une population a risque.]
  295. Use of individual and areal data in evaluating family planning programmes.
  296. Use of sample surveys to evaluate family planning programs in Latin America.
  297. The vaginal contraceptive pill.
  298. Vaginal ring contraception in hypertensive women. [Contraception par anneaux vaginaux chez des femmes hypertendues.]
  299. Value of intrauterine contraception. [Zum Stellenwert der intrauterinen Kontrazeption.]
  300. Vanguard contraceptive users subject of Senegal research.
  301. Vanguard family planning acceptors in Senegal.
  302. Veins and contraception. [Veines et contraception.]
  303. The venous blood stream under the influence of hormonal contraceptive agents. [Die venose Blutstromung unter dem einfluss hormonaler Kontrazeptiva.]
  304. Video: useful tool for delivering family planning messages.
  305. Vulvar effects of the toilet tissue observational routine in the practice of natural family planning [letter]
  306. A welcome family planning service center.
  307. What are the risks inherent in the use of intrauterine contraceptives? [Vilka ar riskerna vid anvandning av intrauterina preventivmedel?]
  308. What inhibits Indian couples not wanting more children from using family planning.
  309. What's new in contraception? [Quoi de neuf en contraception?]
  310. When your patients ask about contraception for the middle years.
  311. Where next with the U.S. export of nonconforming contraceptives?
  312. Which contraceptives don't cause TSS?
  313. Who uses natural family planning?
  314. Women and Depo-Provera usage in Nigeria: chosen or imposed forms of birth control?
  315. Women and family planning services.
  316. Women and family planning.
  317. Women at risk of unintended pregnancy and women in need of family planning: new estimates from the 1982 National Survey of Family Growth.
  318. Women's employment concerns and family planning.
  319. Women's health and family planning.
  320. Women's health and family planning.
  321. Women's perspectives on the Norplant contraceptive implants, Colombia. Final report.
  322. Women, education and family planning.
  323. Workshop in Family Planning Program Management.
  324. World list of family planning addresses.
  325. Worldwide method effectiveness of the Today vaginal contraceptive sponge.
  326. Worldwide trends in funding for contraceptive research and evaluation.
  327. Effects of oral contraceptives on lipoprotein lipids: a prospective study.
  328. Conception-waits in fertile women after stopping oral contraceptives.
  329. Consequences of intrauterine contraception in diabetic women.
  330. Continuation of contraception following menstrual regulation--A Bangladesh experience.
  331. Contraception in adolescence: a review. 1. Psychosocial aspects.
  332. Contraception in adolescence: a review. 2. Biomedical aspects.
  333. Oral contraceptive use and fibrocystic breast disease among pre- and postmenopausal women.
  334. Oral contraceptive use and risk of epithelial ovarian cancer.
  335. Oral contraceptive use: prospective follow-up of women with suspected glucose intolerance.
  336. Oral contraceptives and benign breast disease: a case-control study.
  337. Androgenic action of progestins and possible synandrogenic properties of antiandrogens used in oral contraceptives.
  338. Antifertility activity of a traditional contraceptive pill comprising Acacia catechu, A. arabica and Tragia involucerta.
  339. Antithrombin III in oral contraceptive users and during normotensive pregnancy.
  340. Fertility and contraception of 6 patients with ovarian pregnancy.
  341. Fertility disturbances after taking contraceptives. [A fogamzasgatlo tablettak szedeset koveto fertilitasi zavarok.]
  342. Sources of prescription contraceptives and subsequent pregnancy among young women.
  343. Absence of antibodies to ethinyl estradiol is users of oral contraceptive steroids.
  344. Absence of correlation between oral contraceptive usage and cardiovascular mortality.
  345. Actinomycotic tubo-ovarian abscesses in the presence of an intrauterine contraceptive device. [Aktinomykotische Tubo-Ovarial-Abszesse bei Intrauterinpessar.]
  346. Binding of contraceptive progestogens to receptor proteins in human myometrium and MCF-7 cells.
  347. Breast cancer and oral contraceptive use.
  348. Canadian regulation of contraceptive devices.
  349. The cervical cap: a retrospective study of an alternative contraceptive technique.
  350. Characteristics of women who stop using contraceptives.
  351. Chlamydia trachomatis: important relationships to race, contraception, lower genital tract infection, and Papanicolaou smear.
  352. Clinical experience with a triphasic oral contraceptive.
  353. Clinical trial of a long-acting injectable contraceptive: NET-EN.
  354. Comparative study of Nova-T and Copper-T-200 five-year intra-uterine contraception. [Nova-T and Kupfer-T im Funfjahresvergleich.]
  355. A comparative trial of the Today contraceptive sponge and diaphragm.
  356. A comparison of plasma cholesterol, triglycerides and high density lipoprotein cholesterol levels in women using contraceptive pills and a control group.
  357. Contraception with progestagens in systemic lupus erythematosus.
  358. The contraceptive effect of low dosage oral contraceptives with different progestagen agents. [Der kontrazeptive Effekt niedrig dosierter Ovulationshemmer mitverschiedenen Gestagenen.]
  359. Contraceptive practice among American women, 1973-1982.
  360. Contraceptive practice among American women, 1973-82.
  361. Contraceptives and acute salpingitis.
  362. Copper intravas device (IVD) and male contraception.
  363. A cost-benefit analysis of Thailand's family planning program.
  364. Degradation of the copper-releasing intrauterine contraceptive device and its significance.
  365. Discontinued use of intrauterine contraceptive device and pregnancy loss.
  366. Effect of a new contraceptive ring releasing 20 mcg levonorgestrel daily on blood lipid levels and glucose tolerance.
  367. Effect of an oral contraceptive on adrenal and ovarian androgenic steroids.
  368. The effect of different contraceptive treatments on the serum concentration of dehydroepiandrosterone sulfate.
  369. The effect of low dose oral contraceptives on the initial immune response to infection.
  370. The effect of marital dissolution on contraceptive protection.
  371. Effect of peer counselors on adolescent compliance in use of oral contraceptives.
  372. The effect of two low-dose oral contraceptives and non-hormonal contraception on serum lipids and high-density lipoprotein cholesterol.
  373. Effect of various oral contraceptive combinations on dysmenorrhea.

     

  374. The effectiveness of family planning clinics in serving adolescents.
  375. The effects of federal funding cuts on family planning services, 1980-1983.
  376. Effects of levonorgestrel and desogestrel in low-dose oral contraceptive combinations on serum lipids, apolipoproteins A-I and B and glycosylated proteins.
  377. The effects of nuptiality, contraception and breastfeeding on fertility in developing countries.
  378. Family communication and teenagers' contraceptive use.
  379. Family planning among a group of Colored women.
  380. Family planning in a healthy, married population: operationalizing the human rights approach in an Israeli health service setting.
  381. A family planning risk scoring system for health care providers.
  382. Fertility regulation in nursing women. VI. Contraceptive effectiveness of a subdermal progesterone implant.
  383. Fibrinopeptide A plasma levels during low-estrogen oral contraceptive treatment.
  384. Focal nodular hyperplasia of great extent in the liver after taking oral contraceptives. [A maj extrem nagysagu fokalis nodularis hiperplaziaja oralis fogamzasgatlo szerek szedese kapcsan.]
  385. Husband-wife inconsistencies in contraceptive use responses.
  386. The influence of sequential-type oral contraceptive with ethinylestradiol-sulfonate soft gelatin capsules and norethisterone acetate on carbohydrate metabolism. [Einfluss des Sequenzpraparates mit Athinylostradiolsulfonat-Weichgelatinekapseln und Norathisteronazetat auf den Kohlenhydratstoffwechsel.]
  387. Intracervical release of ST-1435 for contraception.
  388. Issues in fertility control for mentally retarded female adolescents: I. Sexual activity, sexual abuse, and contraception.
  389. IUD deformations and rare complications associated with intrauterine contraception. [IUD-Deformierungen und seltene Komplikationen bei intrauteriner Kontrazeption.]
  390. Kinetics of chloroquine contraceptive steroids in oral contraceptive users during concurrent chloroquine prophylaxis.
  391. Long-term follow-up of children whose mothers used oral contraceptives prior to conception.
  392. Long-term reversible contraception with levonorgestrel-releasing Silastic rods.
  393. Luteinizing hormone-releasing hormone (LHRH) and its analogs for contraception in women: a review.
  394. Microbiology of vaginitis associated with the intrauterine contraceptive device.
  395. Mitotic and apoptotic response of breast tissue to oral contraceptives [letter]
  396. Mortality among young black women using contraceptives.
  397. Multicenter clinical trial of implanted norethindrone pellets for long-acting contraception in women.
  398. Natural family planning (symptothermal method) and objective ovulation indicators--a pilot study. [Naturliche Familienplanung (symptothermale Methode) und objektive Ovulations-parameter--eine Pilotstudie.]
  399. Neem oil as a vaginal contraceptive.
  400. Oral contraception for the adolescent.
  401. Oral contraceptives, pregnancy, and endogenous estrogen in gall stone disease--a case-control study.
  402. Oral contraceptives, pregnancy, and focal nodular hyperplasia of the liver.
  403. Oral contraceptives: the current risk-benefit ratio.
  404. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
  405. Pharmacokinetics of oral contraceptive steroids following the administration of the antimalarial drugs primaquine and chloroquine.
  406. Phenoxybenzamine--an effective male contraceptive pill.
  407. Pituitary and ovarian function and clinical performance during the use of a levonorgestrel-releasing intracervical contraceptive device.
  408. Post-coital contraception with estrogens. Mechanism of action, results and sequelae in a caseload of 123 cases. [Contraccezione post-coitale con estrogenio. Meccanismo di'azione, risultati e sequele in una casistica di 123 casi.]
  409. Predicting adolescent sexual and contraceptive behavior: an application and test of the Fishbein model.
  410. Private physicians and the provision of contraceptives to adolescents.
  411. Prolactin level after prolonged lactation: contraceptive evaluation.
  412. Prolonged elevation of hypothalamic opioid peptide activity in women taking oral contraceptives.
  413. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen.
  414. A prospective multicentre study of the ovulation method of natural family planning. IV. The outcome of pregnancy.
  415. Psychical and sexual effects of hormonal contraceptives--results of a questionnaire. [Psychische und sexuelle Auswirkungen hormonaler Kontrazeptiva--Ergebnisse einer Befragung.]
  416. Public funding of contraceptive, sterilization and abortion services, 1982.
  417. A report on how some young people view the family planning services in the Macclesfield district.
  418. Restovar--new low-dose, combined, oral contraceptive. Effects on serum proteins, free testosterone and clinical efficacy.
  419. Results of establishing medical guidelines for selecting oral contraceptive types in family planning agencies.
  420. Return of fertility after use of the injectable contraceptive Depo Provera: Up-dated data analysis.
  421. Review of the post-coital insertion of intrauterine contraceptive devices. [Postkoitale IUP-Einlage, ein Uberblick.]
  422. The role of epidemiology in the regulation of oral contraceptives.
  423. The secretion of human chorionic gonadotropin-like substance in women employing contraceptive measures.
  424. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
  425. Sex hormone profiles in oligomenorrheic adolescent girls and the effect of oral contraceptives.
  426. Sex, contraception and parenthood: experience and attitudes among urban black young men.
  427. Steroidal postcoital contraception. [Postkoitale Kontrazeption mit Steroidhormonen.]
  428. Studies on some enzymes and sialic acid during progestational contraceptive therapy.
  429. Study on the factors associated with contraceptive discontinuations in Bangkok.
  430. Subcutaneous bioabsorbable pellets of norethindrone for contraception in women: phase I. Clinical study.
  431. Trends in postpartum contraceptive choice.
  432. The use of biodegradable norethisterone implants as a 6-month contraceptive system.
  433. Use of levonorgestrel for postcoital contraception. [Erfahrungen mit Levonorgestrel zur postkoitalen Kontrazeption.]
  434. Use of LHRH agonists and antagonists in male contraception: a review.
  435. Vitamin metabolism and the effects of multivitamin supplementation in oral contraceptive users.
  436. Healthier mothers and children through family planning./Maes e criancas mais sadias atraves do planejamento familiar./Le planning familial ameliore la sante de la mere et de l'enfant./Madres y ninos mas sanos mediante la planificacion familiar.
  437. After contraception: dispelling rumors about later childbearing./Rumores sobre a fertilidad subsequente a anticoncepcao: como dissipa-los./Apres la contraception : dissiper les rumeurs sur la fecondite ulterieure./Disipar rumores negativos sobre la fecundidad después del uso de anticonceptivos.
  438. New developments in vaginal contraception./Novidades em anticoncepcao vaginal./La contraception vaginale : elements nouveaux./Recientes adelantos en la anticoncepcion vaginal.
  439. Effects of oral contraceptives and of the ovarian cycle on hearing performance of 4 and 6 kHz assessed through functional audiometry. [Effets des contraceptifs oraux et du cycle ovarien sur la performance auditive 4 et 6 kHz. Mise en evidence par audiometrie fonctionnelle.]
  440. Effects of oral contraceptives on diazepam-induced psychomotor impairment.
  441. Effects of oral contraceptives on vitamins B6, B12, C, and folacin.
  442. Effects of Organized Family Planning Programs on U.S. Adolescent Fertility, 1970-1975 [MRDF]
  443. The effects of social setting and family planning programs on recent fertility declines in developing countries: a reassessment.
  444. Effects of the LHRH-analogue Buserelin given discontinuously as a contraceptive on ovarian cycle and lipometabolism.
  445. Effects of the ovarian and contraceptive cycles on absolute thresholds, auditory fatigue and recovery from temporary threshold shifts at 4 and 6 kHz.
  446. Elise Ottesen-Jensen and the emergence of the International Planned Parenthood Federation, 1945-1953.
  447. Endocarditis and the intrauterine contraceptive device [letter]
  448. Endometrial curettage in abnormal vaginal bleedings in 1964 and 1983 at the Panti Rapih Hospital, Yogyakarta, and family planning. [Kerokan endometrium pada perdarahan abnormal vaginal pada tahun 1964 dan 1983 di Rumah Sakit Panti Rapih, Yogyakarta, dan keluarga Berencana.]
  449. Ensuring informed choice for voluntary surgical contraception: guidelines for counseling and for informed consent.
  450. Epidemiology and oral contraception--the way ahead.
  451. Establishing or improving surgical contraception programs in outpatient facilities: a professional guide.
  452. Estimating impact of Malaysian family planning programme on births: a comparison of matched acceptor and non-acceptor birth rates.
  453. Estrogen, progesterone dosage varies in new oral contraceptive.
  454. Ethanol metabolism in women taking oral contraceptives.
  455. The ethics of family planning.
  456. Ethnic differences in contraceptive use in Sri Lanka.
  457. Ethnic differences in contraceptive use in Sri Lanka.
  458. An evaluation of a program in decision-making about contraception.
  459. Evaluation of Development Associates, Inc. contract (AID/DSPE-C-0060) for paramedical, auxiliary, and community (PAC) family planning personnel training in Latin America and the Caribbean (LAC)
  460. Evaluation of family planning education and training.
  461. Evaluation of family planning motivation kits, Song Be province, Vietnam, May 1984.
  462. Evaluation of family planning program in Taiwan, ROC.
  463. Evaluation of family planning programs. [Evaluacion de programas de planificacion familiar.]
  464. An evaluation of in service training on population/family planning information system (19 May - 9 July 1981, Bangkok)
  465. Evaluation of mobile family planning education program in factories.
  466. An evaluation of the age-specific fertility rates from Mexico's 1979 Contraceptive Prevalence Survey.
  467. Evaluation of the family planning program in Taiwan, Republic of China.
  468. Evaluation of the population and development program's impact on family planning in rural Egypt.
  469. Evaluation system of the National Population and Family Planning Program.
  470. An evaluational survey of training programmes in the field of family planning and population.
  471. Evidence of immunosuppressor factor in the serum of women taking oral contraceptives.
  472. Examinations with Anteovin, a biphasic contraceptive.
  473. Comparisons of private physician and clinic contraceptive services [tables]
  474. Concepts and issues in family planning: guidelines for nurses, midwives, and other health personnel.
  475. Conceptual framework for family planning development in the congested areas of Bangkok Metropolis.
  476. Condom use in Haiti: an overview of male contraceptive acceptance and some findings from focus group research.
  477. A consumer baseline survey on behaviour, attitudes, and practices of the Jamaican contraceptive users and potential users.
  478. Contact lens wear problems--implications of penicillin allergy, diabetic relatives, and use of birth control pills.
  479. Continuing evaluation and research needs in national family planning promotion: plus ca change, plus c'est la meme chose.
  480. Contraception and cardiac disease: can the pill, IUD be prescribed?
  481. Contraception and chronic illnesses: cardiac disease.
  482. Contraception and pregnancy in epileptics. [Contraception et grossesse chez les epileptiques.]
  483. Contraception and sexually transmissible diseases.
  484. Contraception and the mentally handicapped.
  485. Contraception and under-16s.
  486. Contraception and unwanted pregnancy.
  487. Contraception at caesarean delivery.
  488. Contraception by hormonal implant method: medico-demographic observations. [La contraccezione a mezzo di implants ormonali, osservazioni medico-demografiche.]
  489. Contraception during perimenopausal years is important issue for patients, clinicians.
  490. Contraception for adolescents.
  491. Contraception for the "morning after"--a little known possibility. [Schwangerschaftsverhutung am "Morgen danach." Eine zu wenig genutzte Chance.]
  492. Contraception for the older woman.
  493. Contraception for women over 40. [La contraception apres 40 ans.]
  494. Contraception in a clinical epidemiologic survey. [La contraccezione in un servizio consultoriale indagine epidemiologica.]
  495. Contraception in girls in her teens. [Contraception chez l'adolescente.]
  496. Contraception in Italy: a study of current use, knowledge and perceptions of contraceptive methods.
  497. Contraception in Switzerland: a sociological study of contraceptive usage and attitudes toward abortion among Swiss married couples. [Kontrazeption in der Schweiz: eine soziologische Untersuchung der Anwendung von Methoden zur Empfangnisverhutung und der Einstellungen zum Schwangerschaftsabbruch bei Schweizer Ehepaaren.]
  498. Contraception in the adolescent female. Issues and controversies. [La contraception de l'adolescente. Enjeux et controverses.]
  499. Contraception in the population/development equation.
  500. Contraception in Turkey: methods and socioeconomic background--a presentation based on the most recent data available. [Antikonzeptiva in der Turkei: Methoden und sozio-okonomische Hintergrunde--eine Darstellung aufgrund neuester Daten.]

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.